User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Content deleted Content added
SDZeroBot (talk | contribs)
Updating report
SDZeroBot (talk | contribs)
Updating report
(5 intermediate revisions by the same user not shown)
Line 1:
{{User:SDZeroBot/NPP sorting/header|count=1320|date=2831 August 2025|ts=01:4946, 2831 August 2025 (UTC)}}
 
{| class="wikitable sortable"
Line 9:
! scope="col" style="width: 10em;" | Creator (# edits)
! scope="col" style="width: 4em;" | Notes
|-
| 2024-01-15
| [[Gadolinium(III) selenate]] <small>(Chemical compound)</small>
| Gadolinium(III) selenate is an inorganic compound with the [[chemical formula]] Gd<sub>2</sub>(SeO<sub>4</sub>)<sub>3</sub>. It exists as the anhydrate and octahydrate. The octahydrate transforms into the anhydrate when heated to 130&nbsp;°C.
| Stub
| data-sort-value=275322447 | [[Special:Contribs/JesusisGreat7Praseodymium-141|JesusisGreat7Praseodymium-141]] (275322447)
|
|-
| 2024-01-11
| [[Samarium(III) antimonide]] <small>(Chemical compound)</small>
| Samarium antimonide is a binary inorganic compound of [[samarium]] and [[antimony]] with the formula SmSb. It forms crystals.
| Stub
| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)
|
|-
| 2024-01-18
| [[Porous polymer]]
| Porous polymers are a class of [[porous media]] materials in which [[monomer]]s form [[2D polymer|2D]] and [[3D polymers]] containing angstrom- to nanometer-scale pores formed by the arrangement of the monomers. They may be either crystalline or amorphous. Subclasses include [[covalent organic framework]]s (COFs), [[hydrogen-bonded organic framework]]s (HOFs), [[metal-organic framework]]s (MOFs), and [[porous organic polymer]]s (POPs).
| Start
| data-sort-value=8895 | [[Special:Contribs/Michael7604|Michael7604]] (8895)
|
|-
| 2024-01-22
| [[Praseodymium monoselenide]] <small>(Chemical compound)</small>
| Praseodymium monoselenide is a compound with the chemical formula PrSe. It forms crystals.
| Stub
| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)
|
|-
| 2024-01-26
| [[Iron(III) selenite]] <small>(Chemical compound)</small>
| Iron(III) selenite is an inorganic compound with the chemical formula Fe<sub>2</sub>(SeO<sub>3</sub>)<sub>3</sub>. It exists anhydrous form and as various hydrates. The heptahydrate is produced by the reaction of [[ferric chloride]] and [[selenous acid]] (or [[sodium selenite]]) at a pH of 1.05.
| Start
| data-sort-value=22447 | [[Special:Contribs/Praseodymium-141|Praseodymium-141]] (22447)
|
|-
| 2024-11-10
Line 14 ⟶ 49:
| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.
| Start
| data-sort-value=83828392 | [[Special:Contribs/Tokisaki Kurumi|Tokisaki Kurumi]] (83828392)
|
|-
| 2024-01-10
| [[Fudosteine]] <small>(Chemical compound)</small>
| Fudosteine (Cleanal) is a [[mucolytic agent]]. In Japan, it is approved for the treatment of [[bronchial asthma]], [[chronic bronchitis]], [[pulmonary emphysema]], [[bronchiectasis]], [[pulmonary tuberculosis]], [[pneumoconiosis]], atypical [[mycobacterial disease]], and [[diffuse panbronchiolitis]].
| Stub
| data-sort-value=5014 | [[Special:Contribs/Innerstream|Innerstream]] (5014)
|
|-
Line 28 ⟶ 70:
| <sup>177</sup>Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.
| C
| data-sort-value=56985704 | [[Special:Contribs/Noxoug1|Noxoug1]] (56985704)
|
|-
Line 35 ⟶ 77:
| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.
| C
| data-sort-value=56985704 | [[Special:Contribs/Noxoug1|Noxoug1]] (56985704)
|
|-
Line 42 ⟶ 84:
| Vatinoxan, originally known as MK-467, is an [[Alpha-2_adrenergic_receptor#Antagonists|α<sub>2</sub>-adrenergic receptor antagonist]] used in veterinary medicine alongside [[Alpha-2_adrenergic_receptor#Agonists|α<sub>2</sub>-adrenergic receptor agonists]] to counteract [[vasoconstriction]] and [[hypertension]] while maintaining sedation. Vatinoxan does not cross the [[blood–brain barrier]] giving it a unique pharmacological profile compared to the other α<sub>2</sub>-adrenergic receptor antagonists and distinct clinical application.
| C
| data-sort-value=498499 | [[Special:Contribs/Sacristy|Sacristy]] (498499)
|
|-
Line 56 ⟶ 98:
| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].
| C
| data-sort-value=56985704 | [[Special:Contribs/Noxoug1|Noxoug1]] (56985704)
|
|-
Line 63 ⟶ 105:
| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].
| Start
| data-sort-value=8795788166 | [[Special:Contribs/Ramblersen2|Ramblersen2]] (8795788166)
|
|-
| 2025-05-31
| [[Musahaqah]]
| Musaheqeh ({{Langx|ar|مساحقه}}) is a legal and religious term. In [[Fiqh|Islamic jurisprudence]] ([[fiqh]]) and under the [[Islamic Penal Code of Iran]], musaheqeh refers to a situation in which an adult, mentally competent, and consenting [[woman]] brings her [[Sex organ|genitalia]] into contact with the genitalia of another woman.
| Stub
| data-sort-value=2753 | [[Special:Contribs/JesusisGreat7|JesusisGreat7]] (2753)
|
|-
Line 77 ⟶ 112:
| The Hellenic Championship is an [[ATP 250 tournaments|ATP 250 tournament]] held in [[Athens]], [[Greece]]. The event is played on indoor [[hardcourt]] at the [[OAKA Basketball Arena]], a multi-purpose venue that was used for the [[2004 Summer Olympics]]. It replaces the [[Belgrade Open]] on the calendar and it is scheduled to debut in November 2025.
| Stub
| data-sort-value=40054021 | [[Special:Contribs/Haddad Maia fan|Haddad Maia fan]] (40054021)
|
|-
| 2025-0508-0413
| [[Erythrocyte-basedStructural drugDynamics deliveryResponse Assay]] <small>(DrugBiochemical deliveryanalysis methodprocedure)</small>
| The structural dynamics response (SDR) assay is a type of [[biophysical]] test used to measure [[ligand binding]] to a target [[protein]]. The assay is configured as a simple mix and read format that can be conducted in very low volumes, therefore suitable for [[drug discovery]] applications such as [[high throughput screening]] (HTS), or in the development of a drug candidate during [[medicinal chemistry]] optimization cycles.
| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.
| CStart
| data-sort-value=6374 | [[Special:Contribs/DrugDelivery2025Hoffmacs|DrugDelivery2025Hoffmacs]] (6374)
|
|-
| 2025-0508-3127
| [[Ferrugine]] <small>(Chemical compound)</small>
| Ferrugine is a [[tropane alkaloid]] discovered in the basic [[extract]] of the Australian rainforest tree ''[[Darlingia ferruginea]]'' where it occurs in the leaves and stems. The structure has been [[Chemical_structure#Structural_elucidation|determined]] through [[spectroscopic analysis]] and confirmed by [[chemical synthesis]].
| Stub
| data-sort-value=0 | [[Special:Contribs/2.101.56.53|2.101.56.53]]
|
|-
Line 94 ⟶ 136:
|
|-
| 2025-0805-1304
| [[StructuralErythrocyte-based Dynamicsdrug Response Assaydelivery]] <small>(BiochemicalDrug analysisdelivery proceduremethod)</small>
| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.
| The structural dynamics response (SDR) assay is a type of [[biophysical]] test used to measure [[ligand binding]] to a target [[protein]]. The assay is configured as a simple mix and read format that can be conducted in very low volumes, therefore suitable for [[drug discovery]] applications such as [[high throughput screening]] (HTS), or in the development of a drug candidate during [[medicinal chemistry]] optimization cycles.
| C
| data-sort-value=6 | [[Special:Contribs/DrugDelivery2025|DrugDelivery2025]] (6)
|
|-
| 2004-07-29
| [[Figure of Insensitivity]]
| Figure of Insensitivity (''F of I'') is an inverse scale of measure of the impact [[shock sensitivity|sensitivity]] of an [[explosive]] substance. In this particular context the term 'Insensitivity' refers to the likelihood of initiation/[[detonation]] by impact, [[friction]], [[electrostatic discharge]], application of [[flame]], etc.
| Start
| data-sort-value=3740 | [[Special:Contribs/Hoffmacs20.133.0.11|Hoffmacs20.133.0.11]] (374)
|
|}
<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] <sup>''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''</sup> at 01:4946, 2831 August 2025 (UTC)</span>